Tecartus: the first and only CAR T treatment for relapsed or refractory mantle cell lymphoma, FDA approved
The U.S. Food and Drug Administration ( FDA ) has granted accelerated approval to Tecartus ( Brexucabtagene autoleucel, formerly KTE-X19 ), the first and only approved chimeric antigen receptor ( CAR ...
read article